A. Lennard

发表

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

J. Gribben, G. Salles, L. Sehn, 2016, The Lancet. Oncology.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

J. Gribben, G. Salles, L. Sehn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

C. Crawley, D. Marin, J. Goldman, 2003, Leukemia.

Stem cell transplantation

A. Lennard, G. Jackson, 2000, BMJ : British Medical Journal.

Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).

B. Angus, G. Jackson, K. Wood, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party.

P. Donnan, R. Prescott, S. Proctor, 1992, Leukemia & lymphoma.

Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent.

S. Turner, G. Gui, J. Bristol, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study

A. Davies, K. Wood, A. Lopes, 2018, Bone Marrow Transplantation.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

B. Coiffier, J. Sancho, C. Buske, 2018, The Lancet. Haematology.

Telomere Shortening Correlates with Prognostic Score at Diagnosis and Proceeds Rapidly during Progression of Chronic Myeloid Leukemia

T. Holyoake, M. Drummond, A. Lennard, 2004, Leukemia & lymphoma.

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

A. Hall, J. Irving, L. Minto, 2004, Clinical chemistry.

Development of Real-Time Quantitative Polymerase Chain Reaction Assays to Track Treatment Response in Retinoid Resistant Acute Promyelocytic Leukemia

P. Vyas, D. Grimwade, J. Jovanovic, 2011, Front. Oncol..

Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study.

A. Ng, L. Specht, R. Tsang, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Stem cell transplantation

G. Jackson, A. Lennard, 2000, BMJ : British Medical Journal.

Rapid onset of chronic granulocytic leukaemia after treatment for Hodgkin's disease

G. H. Jackson, S. Proctor, A. Lennard, 1994, British journal of haematology.

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

J. Esteve, N. Osheroff, M. Voso, 2008, Blood.

Late‐appearing MLL rearrangement arising as a secondary change in adult acute myeloid leukemia

N. Bown, A. Lennard, D. Rowe, 2002, Genes, chromosomes & cancer.

Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies

A. Lennard, M. Sieniawski, 2011, Current hematologic malignancy reports.

Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.

S. Proctor, P. Revell, A. Lennard, 2010, Blood.

Collection of bcr/abl Negative Peripheral Blood Progenitor Cells in Newly Diagnosed Patients with Chronic Myeloid Leukaemia

J. Irving, S. Proctor, A. Dickinson, 1996 .

Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. A prospective study on behalf of the east of Scotland and Newcastle lymphoma group (ESNLG)

Angela C. Dawson, R. Prescott, B. Angus, 1989, Hematological oncology.

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom

S. Montoto, R. Marcus, P. McKay, 2017, Bone Marrow Transplantation.

Management of non-Hodgkin's lymphomas

A. Lennard, P. Mounter, 1999, Postgraduate medical journal.

chronic myeloid leukemia immunotherapy in patients undergoing reduced intensity allografts for Post-transplant imatinib as a strategy to postpone the requirement for

C. Craddock, K. Piper, J. Byrne, 2013 .

Autologous bone marrow transplantation in acute lymphoblastic leukaemia.

G. Jackson, A. Lennard, P. Taylor, 1994, Blood reviews.

Prognostic significance of Epstein-Barr virus association in Hodgkin's disease.

F. Alexander, D. Onions, B. Angus, 1994, European journal of cancer.

Hydroxyurea-induced acute alveolitis in a Patient with chronic myeloid leukaemia

G. Jackson, J. Ledingham, S. Proctor, 2004, Cancer Chemotherapy and Pharmacology.

Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.

G. Jackson, H. Lucraft, A. Lennard, 1993, British Journal of Cancer.

Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement.

R. Aguiar, A. Chase, A. Reiter, 1997, Blood.

transplantationmedicine, and the future: Stem cell

G. Jackson, A. Lennard, 2006 .

High Dose Ifosfamide in Combination with Etoposide and Epirubicin Followed by Autologous Stem Cell Transplantation in the Treatment of Relapsecd/Refractory Hodgkin's Disease: a Report on Toxicity and Efficacy On behalf of the Scotland and Newcastle Lymphoma Group

N. Russell, N. Russell, B. Angus, 2000, Leukemia & lymphoma.

Early high dose chemotherapy intensification with autologous bone marrow transplantation in lymphoma associated with retention of fertility and normal pregnancies in females. Scotland and Newcastle Lymphoma Group, UK.

G. Jackson, P. Robinson, A. Lennard, 1997, Leukemia & lymphoma.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients.

N. Russell, S. James, I. Roberts, 2002, The Journal of hospital infection.

A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma

J. Berkhof, C. Meijer, W. Verbeek, 2015, Clinical Cancer Research.

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

J. Leonard, F. d'Amore, K. Venkatakrishnan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.

C. Craddock, K. Piper, S. Siddique, 2007, Blood.

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

M. Baccarani, C. Sawyers, H. Kantarjian, 2002, Blood.

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party.

P. Donnan, R. Prescott, R. Boys, 1991, European journal of cancer.

Lymphomatoid papulosis: response to treatment with recombinant interferon alfa-2b.

G. Jackson, A. Lennard, J. Marks, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low frequency of myelodysplasia after autologous bone marrow transplantation

G. Jackson, A. Lennard, P. Taylor, 1995, The Lancet.

CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.

R. Prescott, D. Cameron, W. Thompson, 1997, European journal of cancer.

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

R. Bociek, F. Cavalli, S. Lade, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The pharmacokinetics of melphalan in patients with multiple myeloma: An intravenous/oral study using a conventional dose regimen

M. Rawlins, A. Lennard, K. Woodhouse, 2004, European Journal of Clinical Pharmacology.

Anaplastic large cell lymphoma in a reconstructed breast using a silicone implant: a UK case report.

V. Wadehra, A. Lennard, N. Collis, 2014, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Combination chemotherapy followed by autologous stem cell transplant for enteropathy‐associated T‐cell lymphoma

A. Lennard, 2007, British journal of haematology.

An effective oral combination in advanced relapsed Hodgkin’s disease prednisolone, etoposide, chlorambucil and CCNU

G. Jackson, S. Proctor, A. Lennard, 2008, Cancer Chemotherapy and Pharmacology.

Cytogenetic abnormalities in a disseminated medulloblastoma.

R. Perry, A. Stuart, A. Pearson, 1993, Medical and pediatric oncology.

Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia

J. Irving, A. Lennard, P. Taylor, 2001, Journal of clinical pathology.

Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant

R. Hollows, L. Robinson, P. Fields, 2020, Transplantation.

Chronic lymphocytic leukaemia terminating in acute myelofibrosis.

A. Lennard, S. Proctor, 1984, Journal of clinical pathology.

Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.

B. Angus, G. Jackson, R. Evans, 1994, British Journal of Cancer.

Mobilization of Ph chromosome‐negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate‐induced complete cytogenetic remission

J. Byrne, D. Marin, T. Holyoake, 2003, British journal of haematology.

Vitamin B-12 and folate deficiency presenting as leukemia.

A. Lennard, 1990, BMJ.

Spontaneous disappearance of psoriasis as presenting feature of oat-cell carcinoma of lung.

T. Lennard, A. Lennard, 1980, British medical journal.

A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III).

R. Prescott, B. Angus, G. Jackson, 2002, European journal of cancer.

Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group.

C. Craddock, J. Byrne, R. Clark, 2002 .

Comments on: Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease, Tsang, et al. Eur J Cancer 1999, 35, 73-78.

G. Jackson, H. Lucraft, A. Lennard, 1999, European Journal of Cancer.

Barium Swallow as an Aid to Pre‐Operative Assessment in Patients with Bronchogenic Carcinoma

A. Lennard, T. Lennard, M. Elliot, 1982, The British journal of clinical practice.

Haematologists in district general hospitals practise evidence based medicine.

M. Galloway, A. Lennard, G. Baird, 1997, Clinical and laboratory haematology.

Aggressive Primary Chemotherapy Plus Autologous Stem Cell Transplantation Improves Outcome for Peripheral T Cell Lymphomas Compared with CHOP-Like Regimens.

S. Proctor, A. Lennard, P. Mounter, 2009 .

Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).

B. Angus, K. Wood, S. Proctor, 2003, Annals of Oncology.

GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

J. Gribben, G. Salles, B. Cheson, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RESULTS OF A PHASE 1 STUDY OF BMN 673, A POTENT AND SPECIFIC PARP-1/2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES

E. Estey, G. Mufti, A. Khwaja, 2014 .